Revenue segments as reported by the company.

Product sales

Other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Acquired in-process research and development

Selling, general and administrative

Other

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Amgen

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. Its products include the following brands: Aranesp, Aimovig, KANJINTI, EVENITY, AMGEVITA, AVSOLA, BLINCYTO, MVASI, Corlanor, Enbrel, EPOGEN, IMLYGIC, Kyprolis, Neulasta, NEUPOGEN, Nplate, Parsabiv, Prolia, Repatha, Sensipar, Vectibix, Otezla, RIABNI, and XGEVA. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Amgen reports robust Q4 results, navigates pricing challenges for growth

Amgen's Q4 earnings call highlighted strong performance, innovative products, and strategic acquisitions driving growth. Challenges in pricing strategies and market dynamics require careful navigation. Opportunities in promising data, asset advancements, and access strategies position Amgen for future success.

Amgen reports robust Q1 performance, eyes growth in Asia-Pacific

Amgen's Q1 2023 earnings call highlighted strong performance, innovative R&D focus, and growth in key markets like Asia-Pacific.
Despite challenges with inventory issues and pricing dynamics, the company remains optimistic about long-term growth opportunities and biosimilar competitiveness.
Opportunities lie in addressing complex disorders like obesity, expanding market presence, and driving growth in key product franchises.
Overall, Amgen's strategic focus on performance, international expansion, and pipeline advancements positions the company for sustained growth and innovation.

Amgen reports robust Q2 earnings, eyes growth through strategic acquisitions

Amgen's strong Q2 performance, robust sales growth, and strategic acquisitions position the company for continued success.
While facing challenges in competitive markets and potential legal risks, Amgen's focus on innovation and portfolio expansion presents growth opportunities.
With a solid financial outlook, increased R&D investments, and a focus on shareholder returns, Amgen remains well-positioned for future growth.
Updates on key products, positive trial results, and strategic initiatives underscore Amgen's commitment to advancing healthcare and driving value creation.

Amgen reports revenue and earnings growth, eyes AI for innovation

Amgen's Q3 performance showed revenue and earnings growth, driven by strong global volume and record sales for key medicines. The company's pipeline progress and strategic focus on R&D highlight a commitment to innovation and future growth. While challenges exist around acquisition integration and market competition, Amgen is poised for continued success through the end of the decade and beyond.

Amgen reports record sales in Q4 2023, eyes rare diseases

Amgen's Q4 2023 performance was robust, driven by record sales and strategic acquisitions.
Despite short-term challenges like tax payments impacting cash flow, the company remains confident in its long-term growth trajectory.
Opportunities lie in expanding the rare disease portfolio, advancing R&D initiatives, and exploring new therapeutic areas.
Overall, Amgen's strong financials, diverse pipeline, and focus on innovation position it well for sustained growth and global impact.

Amgen reports strong Q1 growth, eyes new markets and innovations

Amgen's Q1 2024 performance reflects strong sales growth, financial resilience, and continued momentum in key product segments, positioning the company for future success.
Despite challenges in competitive differentiation, product launches, and regulatory complexities, Amgen's strategic strengths in innovation, manufacturing, and market expansion offer a solid foundation for growth.
The company's focus on addressing unmet medical needs, exploring new therapeutic areas, and advancing pipeline candidates underscores its commitment to driving patient impact and capturing market opportunities.
With a robust financial outlook, ongoing Phase III trials, and a proactive approach to product development, Amgen is well-positioned to achieve its revenue targets, drive innovation, and deliver value to shareholders.

Amgen reports strong Q2 earnings, eyes growth in diverse markets

Amgen's Q2 2024 earnings call highlighted robust revenue growth, strong sales performance, and promising pipeline developments across various therapeutic areas.
While facing challenges in market dynamics and product differentiation, Amgen's strategic focus on rare diseases and innovative therapies positions it well for future growth.
With a clear outlook on capital allocation, continued expansion in endocrinology, and opportunities in the obesity market, Amgen remains poised for sustained success.

Amgen reports strong Q3 earnings and outlines growth strategies

Amgen's Q3 2024 earnings call highlighted robust financial performance, progress in pipeline development, and strategic initiatives for future growth. With a strong revenue outlook and focus on innovation, Amgen remains well-positioned in the biopharmaceutical industry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. It operates through Human Therapeutics segment. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Horizon Pharma

The agency previously argued the merger could harm patients who are prescribed Horizon's two fastest-growing drugs.

Amgen's $27.8 Billion Purchase Of Horizon Therapeutics On After FTC Settlement

The Federal Trade Commission makes provision that prohibits “bundling” discounts for some medications.

Amgen, Horizon Therapeutics Stocks Rise After FTC Settlement Over $27.8 Billion Merger

Amgen stock jumped Friday after the company confirmed the FTC officially cleared its $28 billion acquisition of Horizon Therapeutics.

Amgen, Horizon Therapeutics Stocks Jump After FTC Clears Their $28 Billion Marriage

The Federal Trade Commission reached a deal with Amgen Inc. AMGN, -0.60% to approve its $27.8 billion acquisition of Horizon Therapeutics plc, HZNP, -0.07% the agency announced Friday.

FTC settles with Amgen over $27.8 billion takeover of Horizon Therapeutics

The U.S. Federal Trade Commission has allowed drugmaker Amgen Inc to move ahead with its $27.8 billion deal to buy Horizon Therapeutics , CNBC reported on Friday.

U.S. FTC allows Amgen to move forward with $27.8 bln Horizon deal - CNBC

The FTC had filed a lawsuit in May seeking to block the acquisition, arguing that the deal would "stifle competition" in the pharmaceutical industry.

FTC, Amgen strike deal to allow $27.8 billion Horizon Therapeutics acquisition to move forward

Astellas Pharma Inc

Bristol-Myers

Johnson & Johnson

Eli Lilly

Merck

Novo Nordisk

Novartis

Major pharmaceutical companies including Johnson & Johnson NYSE: JNJ, Novartis AG NYSE: NVS, Bristol-Myers Squibb (NYSE: BMY), Merck & Co., Inc. NYSE: MRK, Eli Lilly & Co. NYSE: LLY and Amgen Inc. NASDAQ: AMGN were trading normally following news that their drugs would be subject to next year's Medicare price negotiations.

How Much Pain Will Lower Medicare Prices Cause for Pharma Stocks?

THOUSAND OAKS, Calif. , Aug. 31, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the 2023 Wells Fargo Healthcare Conference at 9:30 a.m.

AMGEN TO PRESENT AT THE 2023 WELLS FARGO HEALTHCARE CONFERENCE AND THE CITI GLOBAL HEALTHCARE CONFERENCE

Biotech stocks have underperformed the broad market since May, when the Federal Trade Commission moved to block Amgen's proposed acquisition of Horizon Therapeutics. The FTC was aiming to prevent Amgen from stifling potential competition for two of Horizon Therapeutics' drugs.

Is This the Green Light Biotech Stocks Have Been Waiting For?

AstraZeneca

The negotiations with participating drug companies are likely to happen in 2023 and 2024 with the negotiated prices, if any, going into effect in 2026.

Medicare's First Price Negotiation List Targets Expensive Drugs (Revised)

Medicare's First Price Negotiation List Targets Expensive Drugs

AbbVie

Pfizer

Drugs from AbbVie, Bristol and Merck took slots on the list of drugs subject to price cuts. But the pharmaceutical stocks were unmoved.

Blockbusters From AbbVie, Merck, Lilly Highlight List Of 10 Drugs Subject To Price Cuts

Medicare on Tuesday announced the first 10 drugs selected for price negotiations, launching a historic and highly contentious process with big implications for pharmaceutical companies, taxpayers and patients. The selected drugs are the Bristol Myers Squibb Co. BMY, -0.71% blood thinner Eliquis, Boehringer Ingelheim's heart failure drug Jardiance, Johnson and Johnson JNJ, -1.18% blood thinner Xarelto, Merck & Co. Inc. MRK, -1.16% diabetes drug Januvia, AstraZeneca AZN, +0.57% heart failure drug Farxiga, Novartis AG NVS, +0.55% heart failure drug Entresto, Amgen Inc. AMGN, +0.07% rheumatoid arthritis drug Enbrel, AbbVie Inc. ABBV, +0.50% blood cancer drug Imbruvica, Johnson and Johnson psoriasis treatment Stelara, and Novo Nordisk NVO, +0.57% insulin Fiasp.

Merck, Amgen, AbbVie products among first 10 drugs selected for Medicare price negotiations

The FTC's lawsuit against Amgen-Horizon deal is based on unprecedented speculative concerns and would have cleared months ago if it followed well-established precedent.

FTC Attempts To Block Major Biotech Company Merger

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Why Amgen (AMGN) is a Top Value Stock for the Long-Term

Shares of Horizon Therapeutics PLC HZNP, +0.31% gained more than 5% premarket on Monday after the Federal Trade Commission last week paused its legal challenge to Amgen Inc.'s AMGN, -0.09% deal to acquire the biotech company for $27.8 billion. The FTC sued to block the acquisition in May, saying the deal would let Amgen “entrench the monopoly positions” of Horizon treatments for two serious medical conditions.

Horizon Therapeutics shares climb after FTC pauses challenge of deal with Amgen

bluebird bio

Caterpillar

Cisco Systems

Chevron

Dow Inc

Erasca Inc

Intel

iShares Russell 2000 ETF

McDonald's

Walmart

Two new sample Breakout Stocks for Week 35 curated by the MDA model for a 10% short-term upside along with a Dow pick. The Momentum Gauges, S&P 500 Gauges, and Weekly Gauges all continue negative after the longest positive signal since March 2021 on the weekly gauges. Last week three of the four picks gained over the 10% mark, closing up an average of +9.17% for the week with strong Segment 6 momentum.

August MDA Breakout Stocks Week 35 - 2023: High-Frequency Gainers To Give You An Edge

The U.S. Federal Trade Commission (FTC) has suspended its challenge of Amgen's $27.8 billion purchase of Horizon Therapeutics , allowing the FTC to consider whether the agency should settle the case, a filing late on Friday showed.

US FTC suspends challenge to block Amgen's $27.8 bln deal for Horizon Therapeutics

The move gives the agency time to weigh a settlement that would allow the deal to close with conditions.

FTC Pauses Challenge to Amgen's $27.8 Billion Deal for Horizon Therapeutics

Amgen is Changing the Cardiovascular Disease Treatment Landscape With New Research on Innovative Lipid Management New Olpasiran Phase 2 Data Demonstrates Continued Reduction of Lp(a) Nearly a Year After the Last Dose Amgen Convenes First LDL Awareness to Action Implementation Consortium THOUSAND OAKS, Calif. , Aug. 26, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced data from the final analysis of the Phase 2 OCEAN(a)-DOSE study of olpasiran, a small interfering RNA (siRNA) during the Late-Breaking Science Session at the European Society of Cardiology (ESC) Annual Meeting being held in Amsterdam.

AMGEN PRESENTS LATE-BREAKING PHASE 2 OLPASIRAN DATA AT ESC 2023

The FTC pulled back one of its efforts to block Amgen's Horizon buyout, according to a document released Friday that sent HZNP stock flying.

Horizon Therapeutics Jumps On A New FTC Development In The Amgen Takeover Battle

Adobe

Altria

Procter & Gamble

Altria is able to stand up to tough environments because consumers are slow to give up their bad habits. Procter & Gamble is the powerhouse name behind some of the world's best-known brands.

4 Surefire Stocks to Buy in the Next Bear Market

Arista Networks

APA Corporation

Constellation Energy Corp

Global Payments

Jacobs Solutions Inc

Regeneron Pharmaceuticals

The S&P 500's plunge in August caught most investors off guard. It's quite a win if you scooped up the handful of gainers in the tough month.

You're An Amazing Stock Picker If You Bought These 8 Stocks This Month

Exelixis

ImmunoGen

The world may be on the mend from the grip of the global pandemic, but the consistent drumbeat for medical innovation remains as unyielding as ever. Amid this backdrop, Biotech stocks present a beacon of hope for humanity and a compelling avenue for savvy investors.

These Are the ONLY 3 Biotech Stocks to Consider in August 2023

THOUSAND OAKS, Calif. , Aug. 21, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) will review data supporting the supplemental New Drug Application (sNDA) for the full approval of LUMAKRAS® (sotorasib) for adults with previously treated locally advanced or metastatic KRAS G12C-mutated non-small cell lung cancer (NSCLC) at a meeting on Oct. 5, 2023.

News for Amgen Stock (AMGN)